07:48 AM EST, 12/11/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) shares climbed by more than 120% in premarket trading after the biopharmaceutical company said a phase 3 trial of CAN-2409 to treat localized prostate cancer met its primary endpoint.

The primary endpoint was to demonstrate a statistically significant improvement in disease-free survival compared to the control arm.

The company said that based on the study's results it plans to begin discussions with the US Food and Drug Administration about a regulatory pathway for CAN-2409 to treat localized prostate cancer.